Sheridan, David
5 papers on CoChatORCID 0000-0001-5100-814X
Most cited papers
- Verified
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
Harrison, S. A., Wong, V. W.-S., Okanoue, T., Bzowej, N., Vuppalanchi, R., Younes, Z., Kohli, A., Sarin, S., Caldwell, S. H., Alkhouri, N., et al. (2020) · Journal of Hepatology
Liver Disease Diagnosis and TreatmentLiver physiology and pathology
Cited by 497
- Verified
Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis
Petroff, D., Blank, V., Newsome, P. N., Shalimar, Voican, C. S., Thiele, M., de Lédinghen, V., Baumeler, S., Chan, W. K., Perlemuter, G., et al. (2021) · The Lancet Gastroenterology & Hepatology
Liver Disease Diagnosis and TreatmentUltrasound Imaging and Elastography
Cited by 268
- Verified
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study
Jones, D., Boudes, P. F., Swain, M. G., Bowlus, C. L., Galambos, M. R., Bacon, B. R., Doerffel, Y., Gitlin, N., Gordon, S. C., Odin, J. A., et al. (2017) · The Lancet Gastroenterology & Hepatology
Liver Diseases and ImmunityPeroxisome Proliferator-Activated Receptors
Cited by 191
- Verified
Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis
Mayo, M. J., Vierling, J. M., Bowlus, C. L., Levy, C., Hirschfield, G. M., Neff, G. W., Galambos, M. R., Gordon, S. C., Borg, B. B., Harrison, S. A., et al. (2024) · Alimentary Pharmacology & Therapeutics
Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms
Cited by 39
- Verified
Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
Hirschfield, G. M., Bowlus, C. L., Jones, D. E. J., Kremer, A. E., Mayo, M. J., Tanaka, A., Andreone, P., Jia, J., Jin, Q., Macías-Rodríguez, R. U., et al. (2026) · The Lancet Gastroenterology & Hepatology
Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms
Cited by 34
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free